Certain Options of AnaptysBio, Inc. are subject to a Lock-Up Agreement Ending on 11-JAN-2018.
January 11, 2018
Share
Certain Options of AnaptysBio, Inc. are subject to a Lock-Up Agreement Ending on 11-JAN-2018. These Options will be under lockup for 90 days starting from 13-OCT-2017 to 11-JAN-2018.
Details:
The executive officers and directors have agreed that they will not directly or indirectly, offer, sell, pledge, contract to sell, grant any option to purchase or otherwise dispose of any shares of company’s common stock, shares of common stock which may be issued upon exercise of a stock option or warrant and any other security convertible into or exchangeable for company’s common stock, or enter into any hedging transaction relating to company’s common stock, for a period of 90 days from the date of this prospectus without the prior written approval of Credit Suisse Securities (USA) LLC.
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
ANAPTYSBIO, INC. 
